Spero Therapeutics, Inc.
SPRO · NASDAQ
Market closed$1.58$0.010000 (+0.64%)After hours $1.57 · -0.63%
Key statistics
Previous close$1.57
Open$1.54
Day high$1.64
Day low$1.50
52-week high$3.08
52-week low$1.50
Market cap91.48M
Volume1.25M
Average volume1.23M
P/E ratio6.58
Forward P/E—
EPS0.24
Dividend yield0.00%
Market context
Why it moved
SPRO shares edged modestly higher amid light general market trading, with no specific company-driven catalyst identified, suggesting the slight uptick reflects routine market activity and minor buying interest in the small-cap biotech space.
What is happening
Recent company-specific developments and publisher coverage.
Reuters · July 14, 2026Spero licenses Innovent's experimental immune disease drug for up to $1.1 billionThe Business Journals · July 14, 2026Cambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunologyQuiver Quantitative · July 14, 2026Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029AllSci · July 14, 2026Spero Therapeutics Secures $105M Non-Dilutive FinancingStock Titan · June 25, 2026Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock planSeeking Alpha · June 18, 2026Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO)Investing.com · June 18, 2026Spero Therapeutics stock surges on FDA approval of UtebziGlobeNewswire · May 13, 2026Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update Mt Newswire · July 14, 2026Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing Benzinga · July 14, 2026Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty Benzinga · July 14, 2026Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China Benzinga · June 17, 2026GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs Mt Newswire · June 17, 2026GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections Benzinga · June 17, 2026GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract Infections Benzinga · May 13, 2026Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY Mt Newswire · March 26, 2026Spero Therapeutics Q4 Swings to Profit, Revenue Rises